New active substance can prolong survival with stomach cancer
In Germany, patients can be treated with it from the end of the year. The results of the study, which were published in the New England Journal of Medicine, show that zolbetuximab in combination with chemotherapy delays the progression of the disease and prolongs survival. Prof. Florian Lordick from Leipzig University Medicine, who was involved in the international organisation of the studies, explained that treatment with zolbetuximab led to a significant reduction in the risk of disease progression and death by 29 percent. The antibody zolbetuximab specifically targets the protein claudin 18.2, which is elevated in around a third of patients with gastric cancer. The drug, which reaches the tumour cells via the bloodstream and triggers an immune reaction there, has been researched and tested for over ten years.
Source: Press release University of Leipzig from 14 October 2024
The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.